TCR2
TCR2 is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to express defined TCR alpha/beta chains. TCR2 was founded by Dr. Patrick Baeuerle and MPM Capital. It has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world.
TCR2
Social Links:
Industry:
Biotechnology Health Care Life Science Medical Pharmaceutical Therapeutics
Founded:
2015-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.tcr2.com
Total Employee:
101+
Status:
Active
Contact:
617.475.8469
Email Addresses:
[email protected]
Total Funding:
297.3 M USD
Technology used in webpage:
HSTS IPv6 Akamai Hosted Comcast
Similar Organizations
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Cellares
Cellares is a life sciences technology company that develops the Cell Shuttle to automate cell therapy manufacturing.
Cerevel Therapeutics
Cerevel Therapeutics is a biopharmaceutical company.
Certara
Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development.
Disc Medicine
Disc Medicine is a hematology company
Elicio Therapeutics
Elicio Therapeutics develops an immuno-tumor vaccine to treat cancer.
Insitro
Insitro is a drug discovery and development startup that utilizes machine learning and biology to transform drug discovery.
Rani Therapeutics
Rani Therapeutics develops bio-therapeutics technology for the oral delivery of large drug molecules.
Sanofi
Sanofi is engaged in the research, development, manufacturing, and marketing of innovative therapeutic solutions.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Haitong International Securities Group
Haitong International Securities Group investment in Series B - TCR2
6 Dimensions Capital
6 Dimensions Capital investment in Series B - TCR2
Sirona Capital
Sirona Capital investment in Series B - TCR2
ArrowMark Partners
ArrowMark Partners investment in Series B - TCR2
Alexandria Venture Investments
Alexandria Venture Investments investment in Series B - TCR2
Syno Capital
Syno Capital investment in Series B - TCR2
curative ventures
curative ventures investment in Series B - TCR2
Hillhouse Investment
Hillhouse Investment investment in Series B - TCR2
Cathay Capital
Cathay Capital investment in Series B - TCR2
F2 Ventures
F2 Ventures investment in Series B - TCR2
Official Site Inspections
http://www.tcr2.com Semrush global rank: 13.25 M Semrush visits lastest month: 78
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 15.197.225.128
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "TCR2"
TCR2 - Crunchbase Company Profile & Funding
TCR2 is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a …See details»
Adaptimmune and TCR2 Therapeutics Announce Strategic …
Mar 6, 2023 Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors. Download as PDF March 06, 2023 …See details»
TCR2 Therapeutics Company Profile 2024: Valuation, Investors ...
TCR2 Therapeutics General Information Description. TCR2 Therapeutics Inc is a clinical-stage cell therapy company. It is engaged in developing a pipeline of novel T cell therapies for …See details»
TCR² Therapeutics Appoints Cell & Gene Therapy Manufacturing …
Jul 20, 2021 “TCR 2 is building a fantastic organization. There is a unique combination of talent, technology, passion and opportunity that has me excited to join at this particular moment in …See details»
TCR2 Therapeutics Company Profile - Office Locations ... - Craft
Jun 1, 2023 TCR2 Therapeutics Summary. Company Summary. Overview. TCR , Inc. is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. …See details»
TCR² Therapeutics Announces Partnership with ElevateBio to …
Nov 10, 2020 “After observing meaningful tumor regression in patients at our first, and presumably suboptimal, TC-210 dose, we are pleased to announce a manufacturing …See details»
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 …
Mar 23, 2023 TCR² and Adaptimmune announce strategic combination to create a preeminent cell therapy company focused on treating solid tumors Following the expected Q2 2023 …See details»
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 …
Mar 23, 2023 TCR² and Adaptimmune announce strategic combination to create a preeminent cell therapy company focused on treating solid tumorsFollowing the expected Q2 2023 closing …See details»
TCR² Therapeutics Appoints Cell & Gene Therapy Manufacturing …
Jul 20, 2021 TCR2 Therapeutics . Tue, Jul 20, 2021, 6:45 AM 6 min read. ... “TCR 2 is building a fantastic organization. There is a unique combination of talent, technology, passion and …See details»
TCR² Therapeutics Announces Expansion of U.S. Manufacturing …
Nov 1, 2021 About TCR 2 Therapeutics. TCR 2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid …See details»
TCR² Highlights Gavo-cel Translational Data and Emerging
Apr 10, 2021 TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological …See details»
TCR² Therapeutics Receives FDA Orphan Drug Designation for
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of...See details»
TCR² Therapeutics Announces Pipeline Priorities for 2023
TCR2 Therapeutics . Thu, Jan 5, 2023, 8:45 AM 6 min read. TCR2 Therapeutics. gavo-cel Phase 2 clinical trial now focused on ovarian cancer cohort with first meaningful durability data …See details»
TCR² Therapeutics Establishes Commercial-Scale Cell Therapy
Mar 29, 2021 85,000 square foot state-of-the-art facility being built in Rockville, MarylandAccelerates TCR2’s commercial-scale manufacturing timelines with production...See details»
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022
Mar 23, 2023 TCR² and Adaptimmune announce strategic combination to create a preeminent cell therapy company focused on treating solid tumors; Following the expected Q2 2023 …See details»
TCR² Therapeutics Announces Expansion of U.S. Manufacturing
Nov 1, 2021 TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors.See details»
TCR² Therapeutics Deepens Manufacturing and Immuno …
The Company’s lead TRuC-T cell product candidate, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer …See details»
TCR² Therapeutics to Highlight Off-the-Shelf TRuC-T Cell at
Mar 8, 2022 Following the Company’s presentation at the medical meeting, the AACR poster presentation will be available on the Company’s website at www.tcr2.com. About TCR 2 …See details»
TCR² Therapeutics Reviews Pipeline and Strategy at R&D Day
ET CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of News Today's newsSee details»
TCR² Therapeutics Announces 2022 Strategic Priorities and …
Jan 10, 2022 TCR2 Therapeutics . Mon, Jan 10, 2022, 6:45 AM 6 min read - Safety Review Team (SRT) identified gavo-cel recommended Phase 2 dose (RP2D) at 1x10 8 cells/m 2See details»